未知股票 CARV 深 滬
已收盤
--
0.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 成交量 --
- 最 低 --
- 昨 收 --
- 總市值 0
- 52周最高 --
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 總股本 528.71万
- 歷史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 歷史最低 --
- 每 手 1
- 風險率 0.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Gotham City Research Releases Report On Carvana
BRIEF-Gotham City Research Releases Report On Carvana Jan 28 (Reuters) - GOTHAM CITY RESEARCH RELEASES REPORT ON CARVANA GOTHAM CITY RESEARCH - HOLDS SHORT POSITIONS IN CARVANA STOCK Source text: [ https://tinyurl.com/yp839m2a ] Further company coverage: CVNA.N (( Reuters.Briefs@thomsonreuters.com ;
01-29 00:33
Legend Biotech To Present Six Poster Presentations Featuring Data On CARVYKTI At Tandem Meetings Of ASTCT And CIBMTR
Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding body of evidenceSOMERSET, N.J., Jan. 21, 2026 (GLOBE
01-21 21:10
Legend Reports US$555 Million CARVYKTI Sales for Q4 2025
Legend Reports US$555 Million CARVYKTI Sales for Q4 2025 GenScript Biotech Corporation announced that its associate, Legend Biotech Corporation, reported preliminary net trade sales of approximately US$555 million for CARVYKTI® for the quarter ended 31 December 2025. This update follows previous ann
01-21 20:58
Legend Biotech Reports Preliminary $555 Million CARVYKTI Sales for Q4 2025
Legend Biotech Reports Preliminary $555 Million CARVYKTI Sales for Q4 2025 Legend Biotech Corporation announced preliminary business results for the quarter ended December 31, 2025. According to information provided by Janssen, CARVYKTI® generated approximately $555 million in net trade sales during
01-21 20:30
Johnson & Johnson Q4 sales beat estimates
Johnson & Johnson Q4 sales beat estimates Overview Healthcare co's Q4 sales rose 9.1%, beating analyst expectations Adjusted EPS for Q4 beat analyst expectations Company highlights "significant" innovation in medical portfolio Outlook Johnson & Johnson forecasts 2026 reported sales of $100.5 bln at
01-21 19:28
Carver Bancorp To Deregister Its Common Stock With The SEC And Delist Its Common Stock From The Nasdaq To The OTCQX Market; Last Trading Day On Nasdaq To Be On Or About December 5, 2025
Carver Bancorp, Inc. (the "Company") (NASDAQ:CARV), the holding company for Carver Federal Savings Bank, today announced its voluntary decision to deregister its common stock with the Securities and Exchange Commission
2025-11-19 06:03
Carver Bancorp Q2 EPS $(0.46) Down From $(0.41) YoY, Sales $6.381M Down From $6.579M YoY
Carver Bancorp (NASDAQ:CARV) reported quarterly losses of $(0.46) per share. This is a 12.2 percent decrease over losses of $(0.41) per share from the same period last year. The company reported $6.381 million in sales
2025-11-14 06:12
金斯瑞生物科技盘初涨超3% CARVYKTI®第三季度产生贸易销售净额约5.24亿美元
金斯瑞生物科技（01548）盘初涨超3%，截至发稿，股价上涨1.63%，现报16.18港元，成交额3583.05万港元。 10月14日，金斯瑞生物科技发布公...
2025-10-15 09:44
金斯瑞生物科技：CARVYKTI®于截至2025年9月30日止季度产生贸易销售净额约5.24亿美元
金斯瑞生物科技（01548）公布，根据传奇与Janssen Biotech， Inc．（杨森）于2017年12月21日订立的合作及许可协议，CARVYKTI®于...
2025-10-15 08:37
